Deep Health AI India Ltd: Q1 FY27 Results

Consolidated Revenue: Rs 45.00 Lakh
Consolidated Net Loss: Rs 214.82 Lakh

Reader Takeaway: Pharmaceutical revenue up, but net loss widens significantly, impacting profitability.

What just happened

Deep Health AI India Limited announced its unadjusted financial results for the quarter ended June 30, 2026. The company reported consolidated revenue of Rs 45.00 Lakh, a substantial increase from Rs 15.00 Lakh in the same quarter last year. However, this growth was overshadowed by a consolidated net loss of Rs 214.82 Lakh for the quarter, a stark contrast to the Rs 6.37 Lakh profit recorded in the corresponding quarter of the previous fiscal year.

Why this matters

The results highlight a significant shift in the company's financial performance. While revenue from its pharmaceutical business is showing promising growth, the overall consolidated profitability has deteriorated sharply. This widening loss, impacted by associate company losses and other expenses, raises concerns for investors about the company's path to profitability.

The backstory

Deep Health AI India Limited operates in two main segments: Jewellery and Pharmaceuticals. In recent periods, the company has been focusing on its pharmaceutical business. The latest results indicate a continued pivot, with the jewellery segment reporting no revenue for the quarter, while the pharmaceutical segment contributed the entire Rs 45.00 Lakh revenue.

What changes now

Investors will be closely watching the company's ability to manage its expenses and improve its bottom line. The significant net loss, despite revenue growth, suggests challenges in scaling operations profitably. The performance of the associate company also remains a key factor influencing consolidated results.

Risks to watch

Key risks include the company's ability to achieve sustainable profitability in the pharmaceutical sector, manage its substantial other expenses (Rs 245.88 Lakh), and the impact of losses from its associate concern (Rs 24.92 Lakh). A shift back to profitability is crucial for investor confidence.

Peer comparison

Information on comparable companies within the specific niche of Deep Health AI India Ltd, considering its dual focus and recent performance trends, is not readily available for direct comparison based solely on this filing. However, general trends in the pharmaceutical sector indicate intense competition and the need for efficient operations to achieve profitability.

Context metrics (time-bound)

For the quarter ended June 30, 2026:

• Consolidated Revenue: Rs 45.00 Lakh
• Revenue from Operations (YoY Growth): +200%
• Consolidated Net Loss: Rs 214.82 Lakh
• Profit/(Loss) After Tax (YoY Change): Significant negative swing from Rs 6.37 Lakh profit.
• Loss from Associate: Rs 24.92 Lakh
• Other Expenses: Rs 245.88 Lakh

What to track next

Investors should monitor future quarterly results for sustained revenue growth in the pharmaceutical segment and, critically, for improvements in the company's net loss. Updates on the performance of the associate company and any strategic initiatives to boost profitability will also be important.